Pulmonx Corporation (LUNG) Q2 2025 Earnings Call Transcript

Pulmonx Corporation reported Q2 2025 revenue of $23.9 million, a 15% year-over-year increase, primarily driven by robust international growth of 32% to $9.1 million, which exceeded expectations. However, U.S. revenue growth was slower than anticipated, increasing only 6% to $14.7 million, attributed to operational pressures at interventional pulmonology centers and longer conversion timelines for new commercial initiatives. Consequently, Pulmonx revised its full-year 2025 revenue guidance down to $90 million-$92 million from $96 million-$98 million, while also reducing operating expense guidance to $128 million-$130 million. Despite the U.S. headwinds, the company maintains confidence in its long-term strategy, citing rebounding StratX referrals, leveraging lung cancer screening infrastructure, and progress in new patient identification tools like LungTraX Detect, expecting a U.S. rebound in the second half.

Analysis

Pulmonx Corporation reported mixed Q2 2025 results, characterized by significant outperformance in its international segment being overshadowed by slower-than-anticipated growth in the U.S. market. Total revenue increased 15% year-over-year to $23.9 million, propelled by a 32% surge in international revenue to a record $9.1 million. In contrast, U.S. revenue grew a modest 6% to $14.7 million, missing internal expectations. Management attributed the domestic softness to operational constraints at interventional pulmonology centers, where a focus on robotic bronchoscopy and lung cancer screening has temporarily limited procedure capacity. This dynamic, combined with a longer-than-expected conversion cycle for new commercial initiatives like direct-to-patient outreach and the LungTraX Detect AI tool, prompted a revision of full-year 2025 revenue guidance down to a range of $90-$92 million from $96-$98 million. Despite this recalibration, management provided offsetting positive signals, including record StratX scan referrals in June and July, which serve as a key leading indicator for future procedures. The company also reduced its full-year operating expense guidance to $128-$130 million, ensuring its cash utilization targets remain on track, and reiterated confidence that its strategy of integrating with the expanding lung cancer screening ecosystem will ultimately serve as a long-term tailwind.

Key Decisions for Investors

• Investors should re-evaluate valuation models to reflect the extended timeline for U.S. revenue acceleration, as management now anticipates new commercial initiatives will take one to two additional quarters to materially impact growth.
• Monitor subsequent quarterly reports for conversion rates of the record StratX scans reported in June and July, as this will be the primary validation point for management's thesis of a second-half rebound in the U.S.
• Consider the robust 32% international growth as a partial de-risking factor, but note management's guidance for a moderation in the second half due to seasonality and lower distributor orders from markets like China.
• Acknowledge the company's fiscal discipline in lowering its full-year operating expense guidance in line with the revenue revision, a move that preserves its cash position and mitigates near-term balance sheet risk.